RNA viruses are inhibited by Tetrasilver Tetroxide US Pat 5676977 or US Pat 6485755

Methods of using electron active compounds for managing cancer
US 6485755

Conclusions of IV Tetrasilver Tetroxide Study

1. Tetrasilver tetroxide is preferably delivered in an IV solution to inhibit undesirable side effects.

2. Tetrasilver tetroxide administered by IV appears to stop the growth of the breast cancer.

3. Tetrasilver tetroxide appears to stimulate the normal breast cells and allows them to replace the anaphasic cells in the breast carcinoma.

4. Tetrasilver tetroxide appears to cure infiltrative breast carcinoma in a 24 day period.

5. Tetrasilver tetroxide appears to cure ductile carcinoma special type, medular breast carcinoma in a 30 day period.

6. Tetrasilver tetroxide appears to cure infiltrative lobular breast cancer in a 30 days period.

7. Although certain patients developed mild cases of hepatomegaly, the liver functioning was not impaired as evidenced by the normal levels of liver function enzymes in the blood stream.

http://www.google.com/patents/US6485755